We would love to hear your thoughts about our site and services, please take our survey here.
Wouldn’t it be strange if Avion offered 23.5p per share to buy us out before the New Year?
Very good news!
It’s going to be a great weekend with family and friends either way:)
I wouldn’t want to be out of this over the Bank Holiday weekend, it’s a long time until Tuesday, if we get an announcement from Avion between 16.30 today and 08.00 Tuesday
February 7, 2021 5:00 am by Anna Gross in London
The UK government has selected three British companies to make rapid Covid-19 tests, as it seeks to shake off its reliance on foreign producers and create a domestic diagnostics industry that is prepared for future outbreaks of infectious disease.
The department of health has selected Omega Diagnostics, SureScreen and Global Access Diagnostics to produce up to 2m lateral flow devices (LFDs) per week for the UK, according to two people briefed on the decision.
Coronavirus (COVID-19) Update: FDA Issues New Policy on Dry Heat for Reuse of Certain Respirators
Today, the U.S. Food and Drug Administration (FDA) issued guidance on the use of dry heat to help support the single-user reuse of certain particulate filtering facepiece respirators (FFRs), such as N95 respirators, by health care personnel when there is a limited supply of respirators during the COVID-19 public health emergency.
The immediately-in-effect guidance provides the FDA’s thinking and recommendations regarding the use of bioburden reduction systems that use dry heat to reduce the bioburden, or amount of microorganisms present, on certain respirators for reuse by a single user. Bioburden reduction systems are intended to achieve a certain level in microbial reduction on a device; these are not decontamination systems. Additionally, these systems should only be used in conjunction with existing Centers for Disease Control and Prevention (CDC) recommendations for FFR reuse.
“There exists sufficient evidence demonstrating that there is a reduction of microbial load on certain respirators when exposed to certain dry heat parameters. Bioburden reduction systems can play an important role in the ongoing efforts to help address shortages of FFRs,” said Dr. Binita Ashar, Director of the Division of Surgical Devices in FDA’s Center for Devices and Radiological Health. “Today’s guidance is another example of how FDA is working to address critical shortages in personal protective equipment and help protect health care personnel during the COVID-19 public health emergency.”
Experts today have said that even with a successful vaccine, we will still need to wear masks for the minimum of 2 years!!
It might be worth all of us to re read this again to remind us of the true potential of these masks
A new antiviral facemask which uses nanotechnology to kill viruses including COVID-19 and influenza has been designed and developed by scientists at Pharm2Farm Ltd and Nottingham Trent University.
Instead of the usual three-ply design, the five-ply surgical mask includes an additional antiviral inner layer which incorporates Pharm2Farm’s patented anti pathogenic nanotechnology (GB 2016813.4, 22 October 2020).
On contact with the virus, Pharm2Farms proprietary nanotechnology, which is embedded into the mask material, emits ions that penetrate through the surface envelope of the virus and of destroy the genetic material causing it to die and stop reproducing. The nanotech has a large surface area making the approach more effective at killing the virus without reducing the breathability of the mask. The antiviral inner layer ensures additional protection for both the wearer and those in proximity.
The mask has been designed by Nottingham Trent University scientist and nanotechnology expert, Dr Gareth Cave, and Pharm2Farm’s CEO Dr Karen Davies and is now being commercialised by Pharm2Farm in their new state of the art facilities at Nottingham’s BioCity.
Pharm2Farm has purchased an automated face mask production line, which is on track to be delivered this month (November 2020). The production line, which is manufactured in Europe, has the capacity to produce up to five million anti-viral face masks per month.
Tests showed that the masks, which are Type IIR – meaning they offer the highest level of protection and have a filtration efficiency of 99.98%– were highly effective, at killing more than 90% of the influenza and coronavirus over seven hours, and has been certified to ISO 18184 standards.
The masks include a fluid-repellent layer on the outside – to reduce inhalation of droplets of saliva and mucus that carry COVID-19, the antiviral nanotech layer between two anti-viral filter layers, and a soft hypoallergenic breathable innermost layer.
While current conventional surgical masks block the virus, it can remain on or in the mask while being worn and after it has been disposed of.
The masks are expected to go into production in Nottingham later this month and will be commercially available before Christmas for keyworkers, including healthcare, transport, and food service settings.
IMO, the cost of these injections are going to cost the NHS millions / billions of pounds, it may well be a condition that after the first injection you must wear this mask (and take other precautions ) to prevent any risk associated with the successful outcome after the booster jab three weeks later.